About Ikaria Australia
Ikaria Australia is a Healthcare company based in Kew (Australia) founded in 2010, and was acquired by Mallinckrodt Pharmaceuticals in April 2015. Developer of drug delivery system for treating cardiovascular disorders. Ikaria Australia offers products and services including INOmax Cylinders, INOmax Consumables, THERAKOS Kits, and UVADEX. Its focus areas include Life Sciences, Drug Delivery and Inhaled. Its legal entity is Ikaria Aust Pty Ltd.
Company details
Ikaria is a part of Mallinckrodt Pharmaceuticals. They are developing a drug delivery system for treating congestive heart failure and acute myocardial infarction. Their lead candidate INOMAX which is a nitric oxide inhalation, for treating bronchopulmonary dysplasia (BPD) in premature infants, pulmonary arterial hypertension (PAH), and chronic obstructive pulmonary disease (COPD).
- Headquarters Kew, Australia
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ikariaaust.com
- Social LinkedIn
- Acquired by Mallinckrodt Pharmaceuticals (Apr 2015)
- Legal Name Ikaria Aust Pty Ltd
- Investors
- Acquired byMallinckrodt Pharmaceuticals
(Apr 2015)
Products & Services of Ikaria Australia
Ikaria Australia offers a comprehensive portfolio of products and services, including INOmax Cylinders, INOmax Consumables, THERAKOS Kits, and UVADEX.
Inhalation therapy system for respiratory support in healthcare.
Components for INOmax systems to aid patient treatment.
Photopheresis kits for treating immune disorders.
Drug used in photopheresis procedures for medical applications.
Investors in Ikaria Australia
Ikaria Australia has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specialty pharmaceutical products and diagnostic imaging agents are manufactured. | 1867 | mallinckrodt.com | St. Louis, United States |
Investor details for Ikaria Australia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ikaria Australia
2 dated milestones of Ikaria Australia across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Ikaria Australia is founded.
- Exit Acquired by Mallinckrodt Pharmaceuticals.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ikaria Australia
Ikaria Australia was founded in 2010.
Ikaria Australia is headquartered in Kew, Australia. It is registered at Kew, Victoria, Australia.
Ikaria is a part of Mallinckrodt Pharmaceuticals. They are developing a drug delivery system for treating congestive heart failure and acute myocardial infarction. Their lead candidate INOMAX which is a nitric oxide inhalation, for treating bronchopulmonary dysplasia (BPD) in premature infants, pulmonary arterial hypertension (PAH), and chronic obstructive pulmonary disease (COPD).
Ikaria Australia offers INOmax Cylinders, INOmax Consumables, THERAKOS Kits, and UVADEX.
Ikaria Australia has 1 investor. Key investors include Mallinckrodt Pharmaceuticals.
Ikaria Australia operates through Ikaria Aust Pty Ltd.
Yes. Ikaria Australia was acquired by Mallinckrodt Pharmaceuticals in April 2015.